Skip to main content
OpenTrials
Completed

NCT Number: NCT01405040

Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess Thermodilution Cardiac Output, Global End Diastolic Volume and Extravascular Lung Water

The primary objective of this study is to obtain the TPTD, GEDV and EVLW measurements from existing indwelling femoral arterial Volume View™ catheter and central venous catheters.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum der RWTH Aachen, Aachen, Pauwelsstrasse 30, Germany

Loading trial locations.

About this study

Transpulmonary thermodilution has been proposed to measure transpulmonary thermodilution cardiac output (TPTD), preload (GEDV, global end diastolic volume) and to quantify pulmonary edema (EVLW, extravascular lung water). The method currently available on the market is based on the estimation of time characteristics of the curve (mean transit time and down slope time).

The purpose of this study is to evaluate a new transpulmonary thermodilution method to assess the TPTD, EVLW and GEDV in patients requiring cardiac preload and lung water assessment. Up to one hundred (100) patients will be enrolled at four (4) study sites, (up to 25 subjects at each site). Hôpitaux Universitaires de Genève, Universität Bonn, Stadtspital Triemli Zürich, and Universitätsklinikum Aachen will participate in the study.

This is a prospective, observational data collection study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have clinical need for an indwelling femoral arterial catheter and central venous catheter.
  • Patient, or legal guardian, must sign consent to be in the study prior to data capture.
  • Patient must be at least 18 years old.
  • Patient height and weight are available prior to study.

Exclusion criteria

  • Patients with significant aortic valve regurgitation.
  • Patients being treated with an intra-aortic balloon pump.
  • Patients less than 40 kg in weight.
  • Female patients with a known pregnancy or planned pregnancy.
  • Patient is currently participating in an investigational drug or another device study that clinically interferes with the study endpoints.
  • Patients with peripheral vascular disease.
  • Patients with aortic aneurysm.

Treatment and study plan

Primary outcomes

  1. TPTD, GEDV and EVLW measurements to evaluate the precision and accuracy of a novel algorithm in comparison to the widely accepted TPTD method

    Time frame: Up to 72 hours of femoral arterial catheter dwell time.

    This is not an outcome study. This is an observational Study to obtain TPTD, GEDV and EVLW data to evaluate the precision and accuracy of a novel algorithm in comparison to the widely accepted TPTD method using an approach defined by Bland-Altman.

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Official study title

Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess TPTD, GEDV and EVLW

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jul 29, 2011
Registry last updated
Apr 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.